Kidney Cancer Journal

Talks by Kidney Cancer Journal

A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma

Kidney Cancer Journal | Mar 2018

A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and...

Read More

A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma S2

Kidney Cancer Journal | Mar 2018

A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or...

Read More

A Phase 2 Trial of Lenvatinib 18 mg vs 14 mg Once Daily (QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma S1

Kidney Cancer Journal | Mar 2018

A Phase 2 Trial of Lenvatinib 18 mg vs 14 mg Once Daily (QD) in Combination With Everolimus (5 mg...

Read More

A Phase 1b/2 Trial of Lenvatinib+Pembrolizumab in Patients With Renal Cell Carcinoma S1

Kidney Cancer Journal | Mar 2018

A Phase 1b/2 Trial of Lenvatinib+Pembrolizumab in Patients With Renal Cell Carcinoma S1 Abstract...

Read More

Kidney Cancer Journal, Volume 1; Issue 2

Kidney Cancer Journal | Dec 2017

[searchandfilter id=”13499″...

Read More

1
…
14
15
16
17

Chat with usLiveChat